What Researchers Did
Researchers retrospectively reviewed 105 patients treated with hyperbaric oxygen therapy (HBOT) for radiation-induced hemorrhagic cystitis (RIHC) between 2007 and 2016 to evaluate its efficacy and identify predictive factors for success.
What They Found
After a median of 40 HBOT sessions, a 92.4% success rate was observed in controlling hematuria, though 24.7% of patients experienced recurrence during a median 63-month follow-up. Significant improvements were noted in dysuria, urinary frequency, and hematuria scores (P<.05), with earlier HBOT delivery linked to better response rates and lower recurrences (P<.05).
What This Means for Canadian Patients
Canadian patients experiencing radiation-induced hemorrhagic cystitis may find hyperbaric oxygen therapy to be a safe and effective long-term treatment option for symptom relief. Seeking this therapy sooner after the onset of hematuria could lead to better outcomes and reduced recurrence.
Canadian Relevance
This study was not conducted in Canada and does not include Canadian participants or data.
Study Limitations
As a retrospective study, this research is limited by its reliance on existing medical records, which may introduce selection bias and unmeasured confounding factors.